XRTX Stock Analysis: Buy, Sell, or Hold?
XRTX - XORTX Therapeutics Inc. Common Stock
$2.19
0.03 (1.34%)
▲
5d:
+7.88%
30d:
+8.96%
90d:
-6.41%
WAIT
LOW Confidence
Analysis Updated: Aug 13, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When XRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: XRTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: XRTX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.62
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.63
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XRTX is currently trading at $2.19, which is considered extended relative to its 30-day fair value range of $2.02 to $2.15. From a valuation perspective, the stock is trading at a premium (Forward PE: 2.0) compared to its historical average (1.7). At these levels, the market is pricing in 5.0% annual earnings growth.
Technical Outlook: Technically, XRTX is showing sideways momentum. Immediate support is located at $2.01, while resistance sits at $2.27.
Market Sentiment: XRTX scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.04 (+540.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XRTX is showing sideways momentum. Immediate support is located at $2.01, while resistance sits at $2.27.
Market Sentiment: XRTX scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.04 (+540.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.02 -
$2.15
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.9%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (10/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 540.9% below Wall St target ($14.04)
- BULLISH: Expecting earnings turnaround to 5.0% growth with None% revenue growth
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.02 -
$2.15
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.01
Resistance Level
$2.28
Current Trend
Sideways
Technical data as of
Aug 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.99
Wall Street Target
$14.04
(+540.9%)
Earnings Growth (YoY)
-97.2%
Valuation Premium vs History
+5.0% premium
PE vs Historical
2.0 vs 1.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.0%
(market-implied from PE analysis)
1-Year Target
$2.30
(+5%)
2-Year Target
$2.41
(+10%)
3-Year Target
$2.54
(+16%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
PE COMPRESSION
$2.17
(-1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 14, 2026 5:00 AM ET
Data refreshes hourly during market hours. Next update: 6:00 AM
Data refreshes hourly during market hours. Next update: 6:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 35 SELL |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 63 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 51 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 43 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$140 | 62 BUY |
